FREE Case Review (866) 588-0600

Omniscan Lawsuit

Omniscan, a gadolinium-based contrast agent (GBCA) used during MRIs and other similar medical procedures, has been linked to serious side effects including gadolinium storage condition and gadolinium deposition disease.

Free Confidential Lawsuit Evaluation: If you or a loved one was diagnosed with gadolinium storage condition or gadolinium deposition disease, you should contact our law firm immediately. You may be entitled to compensation by filing a suit against the manufacturer and our lawyers can help.

What is Omniscan?

Omniscan was created as a contrast agent for use in Magnetic Resonance Imaging (MRI) procedures and was approved for use by the US Food and Drug Administration in 1993. Also known as Gadodiamide, Omniscan is considered a paramagnetic agent that tends to generate a localized magnetic field. When protons move through this field, the protons are reorganized in such a way as to provide highly detailed images of the body. The contrast agent can be used for both adults and children and comes in a variety of different sizes for use in the most commonly performed procedures. Packaging Omniscan in different sizes reduces the risk of a physician administering a wrong dosage through confusion of the dosing instructions.

Omniscan is commonly used for producing detailed images of the central nervous system, showing any lesions or tumors that are present. It is also used for the imaging of the chest, abdominal, and pelvic cavities as well as the musculoskeletal system. The contrast agent is administered by IV or injection directly into the blood stream. After allowing the contrast agent to circulate through the system for roughly 45 minutes, the MRI is performed and the images are taken.

Tell MRI Patients About Gadolinium Retention Before Procedures, FDA Warns

The U.S. Food & Drug Administration (FDA) announced on December 19, 2017, that a forthcoming medication guide on gadolinium-based contrast agents (GBCAs) like Omniscan will alert patients that their bodies may retain some of the heavy metal for an extended period – months or even years – after after undergoing MRIs and other similar procedures.

GBCAs seem to be the first class of contrast agent subject to FDA Medication Guide requirements.

“We envisage that the medication guide would be presented to the patient by the same individual who provides a procedure consent form to the patient to read and sign — usually a radiology technician,” FDA said.

Symptoms of Gadolinium Retention

  • Bone pain
  • Joint pain
  • Skin and subcutaneous tissue burning pain
  • “Chemo brain” or “brain fog”
  • Skin changes
  • Thickening / discoloration of the skin
  • “Pins and needles” in the arms and legs
  • Headache

Omniscan Side Effects

The most common side effects resulting from the use of Omniscan include headache, dizziness, and nausea, occurring in around 3% of patients during clinical trials. Some individuals have also experienced an allergic reaction occurring at the site of the injection, causing swelling, rash, and/or pain at the injection site. Other side effects experienced by patients who have taken Omniscan include fatigue, chest pain, fever, flushing, diarrhea, abdominal pain, and increased anxiety.

Allergic Reactions

There is a possibility that a patient that has taken Omniscan may experience a serious adverse allergic reaction to the agent which will require emergency medical treatment to avoid numerous complications and/or death. Omniscan should not be administered to any patient suspected of being sensitive to its components. Any patient who has a history of drug reactions or known allergic reactions should be observed carefully to ensure that their health has not been compromised. Extreme caution should also be taken when administering Omniscan to patients with impaired renal function. Because the contrast agent is eliminated by the kidneys, any patient with impaired renal function may not be able to eliminate the agent from the body quickly enough to avoid serious complications.

Nephrogenic Systemic Fibrosis

Recent studies has linked Omniscan, along with other approved contrast agents containing Gadolinium, to a very serious, debilitating condition known as Nephrogenic Systemic Fibrosis. This condition only affects individuals with moderate to severe renal impairment or renal failure that have taken Omniscan or other FDA approved contrast agents containing Gadolinium prior to undergoing an MRI. The condition is characterized by the tightening and hardening of areas of the skin located on the extremities of the body. Eventually, the areas of affected skin begin to resemble an orange peel and restrict the movement of the joints and muscles beneath the areas of affected skin. There is no cure for the condition and an effective treatment has yet to be found.

Do I Have an Omniscan Lawsuit?

The Pharmaceutical Litigation Group at our law firm is an experienced team of trial lawyers that focus on the representation of plaintiffs in Omniscan lawsuits. We are handling individual litigation nationwide and currently accepting new gadolinium storage condition and gadolinium deposition disease cases in all 50 states.

Free Drug Lawsuit Evaluation: Again, if you or a loved one has been injured by Omniscan side effects, you should contact our law firm immediately. You may be entitled to compensation by filing a suit and we can help.

Free Confidential Case Evaluation

Verified 100% Secure SiteTo contact us for a free review of your potential case, please fill out the form below or call us toll free 24 hrs/day by dialing: (866) 588-0600.
Awards & recognition